Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

During initial examination, in addition to the deformities and disproportions described above, persistent signs of high bone turnover rate were observed: ALP 12.54 µkat/L (6 times ULN), serum bone alkaline phosphatase (BAP) 237.9 µg/L (10 times ULN), procollagen type 1 N-terminal propeptide (P1NP) 1 493 µg/L, beta-crosslaps 2.9 µg/L, hypercalcemia 2.76 mmol/L, low vitamin D (25-OH-vit D) 38.4 nmol/L, hyperuricemia 629 µmol/L, low creatinine 45 µmol/L, slightly increased blood sedimentation rate 26/49.

Source: Biochemical testing results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Juvenile Paget disease with unique compound heterozygous sequence variants in the TNFRSF11B gene

Study design awaiting verification · Orphanet Journal of Rare Diseases · 2025

Original publication title

Juvenile Paget disease with unique compound heterozygous sequence variants in the TNFRSF11B gene

Jana Horackova; Renata Taslerova; Milan Bayer; Jana Nekvindova; Ladislava Pavlikova; Jan M. Horacek; Vladimir Palicka

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The newly described variants of TNFRSF11B extend knowledge of this very rare disease. Early diagnosis and antiresorption treatment prevent further fractures and deformity progression, and improve the patient’s quality of life. This example of osteoprotegerin deficiency may help us better understand its role in skeletal and non-skeletal systems.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Juvenile Paget disease (JPD) is a rare autosomal recessive bone disease characterized by escalated bone metabolism leading to skeletal deformities, susceptibility to fractures, and some extraskeletal findings. This genetic disease is associated with changes in the TNFRSF11B gene encoding osteoprotegerin, an important regulator of osteoresorption. Most published JPD cases have been found to carry homozygous TNFRSF11B variants, while compound heterozygous variants in this gene have been reported only twice.

Source: Background

Abstract: Methods and results

We report the first case of JPD diagnosed in the Czech Republic, who presented with a mild phenotype of this disease. The first bone fractures, appeared at 3 years of age. Other clinical manifestations included typical skeletal deformities, macrocephaly, arched chest, lower extremity valgosity, lateral bowing of the thighs, and anterior bowing of the shins. Minor mixed hearing impairment, angioid stripes of the choroidea, and temporary immunodeficiency were present among extra-skeletal findings. Sanger sequencing was performed on both the patient and the parents to test for the presence of TNFRSF11B sequence variants.

Molecular genetic analysis showed unique compound heterozygous sequence variants in TNFRSF11B: a paternally inherited variant c.30 + 5G > A, p.(?) and a maternally inherited variant c.329G > T, p.(Gly110Val). Both of the variants were analyzed by several in silico predictive tools indicating, for their strongly supported pathogenicity according to American College of Medical Genetics and Genomics standards. Furthermore, we present diagnostic findings, their treatment, and follow-up care.

Source: Methods and results

Abstract: Conclusion

The newly described variants of TNFRSF11B extend knowledge of this very rare disease. Early diagnosis and antiresorption treatment prevent further fractures and deformity progression, and improve the patient’s quality of life. This example of osteoprotegerin deficiency may help us better understand its role in skeletal and non-skeletal systems.

Source: Conclusion
Authors’ abstract

Background

Juvenile Paget disease (JPD) is a rare autosomal recessive bone disease characterized by escalated bone metabolism leading to skeletal deformities, susceptibility to fractures, and some extraskeletal findings. This genetic disease is associated with changes in the TNFRSF11B gene encoding osteoprotegerin, an important regulator of osteoresorption. Most published JPD cases have been found to carry homozygous TNFRSF11B variants, while compound heterozygous variants in this gene have been reported only twice.

Methods and results

We report the first case of JPD diagnosed in the Czech Republic, who presented with a mild phenotype of this disease. The first bone fractures, appeared at 3 years of age. Other clinical manifestations included typical skeletal deformities, macrocephaly, arched chest, lower extremity valgosity, lateral bowing of the thighs, and anterior bowing of the shins. Minor mixed hearing impairment, angioid stripes of the choroidea, and temporary immunodeficiency were present among extra-skeletal findings. Sanger sequencing was performed on both the patient and the parents to test for the presence of TNFRSF11B sequence variants.

Molecular genetic analysis showed unique compound heterozygous sequence variants in TNFRSF11B: a paternally inherited variant c.30 + 5G > A, p.(?) and a maternally inherited variant c.329G > T, p.(Gly110Val). Both of the variants were analyzed by several in silico predictive tools indicating, for their strongly supported pathogenicity according to American College of Medical Genetics and Genomics standards. Furthermore, we present diagnostic findings, their treatment, and follow-up care.

Conclusion

The newly described variants of TNFRSF11B extend knowledge of this very rare disease. Early diagnosis and antiresorption treatment prevent further fractures and deformity progression, and improve the patient’s quality of life. This example of osteoprotegerin deficiency may help us better understand its role in skeletal and non-skeletal systems.

Publication and source details

Original title: Juvenile Paget disease with unique compound heterozygous sequence variants in the TNFRSF11B gene

Jana Horackova; Renata Taslerova; Milan Bayer; Jana Nekvindova; Ladislava Pavlikova; Jan M. Horacek; Vladimir Palicka

Orphanet Journal of Rare Diseases · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100003243Ministerstvo Zdravotnictví Ceské RepublikyMH CZ: DRO (UHHK00179906)Horackova Jana

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:34:29.255377+00:00

DOI: 10.1186/s13023-025-03804-2 · PMC12333066